Top Page
Dr Reddy's Laboratories
(NYSE:RDY)
Dr Reddy's Laboratories (RDY) vs. SPDR S&P 500 ETF (SPY)
Dr Reddy's Laboratories Business Overview & Revenue Model
Dr Reddy's Laboratories Earnings Call Summary
Dr Reddy's Laboratories Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 334.26B | 325.54B | 279.16B | 245.88B | 214.39B | 189.72B |
| Gross Profit | 192.71B | 190.43B | 163.61B | 202.97B | 113.84B | 103.08B |
| EBITDA | 98.08B | 96.67B | 88.42B | 74.43B | 47.74B | 45.71B |
| Net Income | 56.80B | 56.54B | 55.68B | 45.07B | 23.57B | 17.24B |
Balance Sheet | ||||||
| Total Assets | 519.54B | 492.99B | 387.52B | 322.85B | 296.65B | 265.49B |
| Cash, Cash Equivalents and Short-Term Investments | 66.69B | 57.91B | 81.47B | 66.75B | 44.37B | 34.57B |
| Total Debt | 48.64B | 46.77B | 20.02B | 13.47B | 33.84B | 30.31B |
| Total Liabilities | 165.78B | 155.82B | 106.97B | 89.99B | 106.13B | 90.51B |
| Stockholders Equity | 350.06B | 333.39B | 280.55B | 232.86B | 190.53B | 174.98B |
Cash Flow | ||||||
| Free Cash Flow | 14.44B | 12.03B | 18.00B | 40.01B | 9.06B | 23.14B |
| Operating Cash Flow | 52.56B | 46.43B | 45.43B | 58.87B | 28.11B | 35.70B |
| Investing Cash Flow | -57.02B | -58.08B | -40.28B | -41.37B | -26.39B | -22.66B |
| Financing Cash Flow | 8.17B | 18.91B | -3.76B | -26.86B | -2.42B | -298.00M |
Dr Reddy's Laboratories Technical Analysis
Dr Reddy's Laboratories Risk Analysis
Dr Reddy's Laboratories Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | $13.89B | 41.35 | 13.39% | ― | 18.42% | 1.47% | |
71 Outperform | $11.90B | 18.07 | 17.48% | 0.63% | 13.13% | -0.47% | |
66 Neutral | $3.12B | 1,550.00 | 106.97% | ― | 9.81% | ― | |
58 Neutral | $22.79B | ― | -2.31% | ― | 2.43% | 64.37% | |
54 Neutral | $11.86B | ― | -19.77% | 4.72% | -7.47% | -438.39% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $2.97B | ― | -1.32% | 5.30% | -2.32% | 35.46% |
Dr Reddy's Laboratories Corporate Events
Dr. Reddy’s Laboratories announced that it will release its financial results for the quarter and six months ending September 30, 2025, on October 24, 2025, following a board meeting. An earnings call is scheduled for the same day at 19:30 PM IST / 10:00 AM ET to discuss the company’s financial performance. This announcement is significant for stakeholders as it provides insights into the company’s recent financial health and strategic direction.
On September 22, 2025, Dr. Reddy’s Laboratories announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending marketing authorization for AVT03, a biosimilar of Prolia® and Xgeva®, in European markets. This development is a significant step for Dr. Reddy’s as it strengthens their position in the biosimilars market, potentially expanding their reach in Europe and the UK, and offering new treatment options under the tradenames Acvybra® and Xbonzy® upon approval.
Dr. Reddy’s Laboratories has announced a Board meeting scheduled for October 24, 2025, to review and approve the company’s unaudited financial results for the quarter ending September 30, 2025. In compliance with SEBI regulations, the company will close its trading window from September 24 to October 26, 2025, to prevent insider trading. This announcement is significant for stakeholders as it outlines the company’s commitment to transparency and regulatory compliance, which may impact investor confidence and market performance.
On September 17, 2025, Dr. Reddy’s Laboratories announced the transfer of 20.58% of its equity shares by its promoters to private family trusts. This move, involving the transfer of shares by Satish Reddy Kallam and G V Prasad to the VSD Family Trust and GVP Family Trust respectively, is part of a succession planning strategy. The transfer, which was facilitated by an exemption from SEBI, does not alter the management or control of the company, ensuring stability for stakeholders.
On September 16, 2025, Dr. Reddy’s Laboratories announced the launch of Tegoprazan, a novel potassium-competitive acid blocker, in India under the brand name PCAB®. This launch follows their 2022 partnership with South Korea’s HK inno.N Corporation to commercialize Tegoprazan in India and select emerging markets. Tegoprazan is designed to treat acid-related gastrointestinal diseases such as GERD and gastric ulcers, offering a fast onset of action and prolonged gastric pH control. With acid peptic diseases affecting approximately 38% of the Indian population, this launch aims to fill a critical gap in treatment options, potentially improving patient outcomes. Tegoprazan has already been approved in 21 countries and is undergoing registration in several others, including successful completion of a Phase-III trial in the United States.
On September 15, 2025, Dr. Reddy’s Laboratories announced the allotment of 6,475 equity shares to eligible employees as part of its Employees ADR Stock Options Scheme, 2007. This move reflects the company’s ongoing commitment to employee engagement and retention through stock-based incentives. The newly issued shares are fully paid up and rank pari passu with existing shares, contributing to the company’s total issued share capital of Rs. 83,46,14,760. This strategic allocation is expected to enhance employee motivation and align their interests with the company’s growth objectives.
On September 12, 2025, Dr. Reddy’s Laboratories announced that the USFDA completed a Pre-Approval Inspection at their biologics manufacturing facility in Bachupally, Hyderabad. The inspection, which took place from September 4 to September 12, 2025, resulted in a Form 483 with five observations. The company has committed to addressing these observations within the stipulated timeline, which is crucial for maintaining compliance and advancing their market position in the biologics sector.
On September 10, 2025, Dr. Reddy’s Laboratories announced the acquisition of the STUGERON® brand from Janssen Pharmaceutica NV, an affiliate of Johnson & Johnson. This acquisition, valued at USD 50.5 million, includes the STUGERON® portfolio across 18 markets in the APAC and EMEA regions, with India and Vietnam as key markets. The acquisition strengthens Dr. Reddy’s Central Nervous System (CNS) portfolio by expanding into the anti-vertigo segment, leveraging STUGERON®’s leading position in the Cinnarizine market in India. This strategic move aligns with Dr. Reddy’s broader goal of enhancing patient access and aims to reach over 1.5 billion patients by 2030.
Dr. Reddy’s Laboratories recently underwent a GMP inspection by the USFDA at its API Mirfield facility in West Yorkshire, UK, from September 1 to September 5, 2025. The inspection resulted in a Form 483 with seven observations, which the company intends to address within the stipulated timeline, potentially impacting its compliance and operational standards.
On September 3, 2025, Dr. Reddy’s Laboratories received an order from the Joint Commissioner of Customs in Ludhiana, Punjab, imposing a penalty under the Customs Act, 1962, for allegedly availing export incentives irregularly. The penalty amounts to Rs. 3,00,00,000, but the company has assessed that this will not materially impact its financials, operations, or other activities. Dr. Reddy’s is considering filing an appeal against this order.
On September 2, 2025, Dr. Reddy’s Laboratories announced its participation in an upcoming investor conference organized by Investec, scheduled for September 5, 2025. The meeting will be conducted virtually and will involve group discussions with institutional investors, reflecting the company’s ongoing engagement with its stakeholders and efforts to maintain transparency in its operations.
Dr. Reddy’s Laboratories announced that Ms. Archana Bhaskar has resigned from her role as Chief Human Resources Officer (CHRO), effective November 30, 2025. This change in senior managerial personnel is part of the company’s ongoing adjustments and may impact its human resources strategy and operations.
On August 29, 2025, Dr. Reddy’s Laboratories announced the allotment of 21,350 equity shares to eligible employees under its stock options schemes. This move is part of the company’s ongoing efforts to incentivize and retain talent through its Employees Stock Options Scheme, 2002, and Employees ADR Stock Options Scheme, 2007. The issuance of these shares reflects the company’s commitment to employee engagement and aligns with its strategic objectives of enhancing shareholder value.
On August 26, 2025, Dr. Reddy’s Laboratories announced that the Telangana High Court has granted an interim stay on a reassessment order issued by the Income Tax Authority concerning alleged tax escapement following the merger of Dr. Reddy’s Holding Limited into Dr. Reddy’s Laboratories Limited. The company had previously received a show cause notice and an order for reassessment, prompting it to file a writ petition seeking to quash the proceedings. Dr. Reddy’s maintains that there has been no tax escapement and is monitoring the situation closely, with assurances that the company’s promoters will indemnify the company against any liabilities arising from the merger.
On August 20, 2025, Dr. Reddy’s Laboratories announced the allotment of 4,160 equity shares to eligible employees under its Employees Stock Options Scheme, 2002. This move is part of the company’s ongoing efforts to incentivize and retain talent, potentially enhancing employee satisfaction and aligning their interests with the company’s growth objectives.
On August 13, 2025, Dr. Reddy’s Laboratories announced its participation in an upcoming investor conference organized by Centrum Broking, scheduled for August 21, 2025. The meeting will be conducted virtually and will involve group discussions with institutional investors. This engagement reflects Dr. Reddy’s commitment to maintaining transparency and communication with its stakeholders, potentially impacting investor relations and market perception.
On August 7, 2025, Dr. Reddy’s Laboratories received an Establishment Inspection Report (EIR) from the United States Food & Drug Administration (USFDA) for its API manufacturing facility in Miryalaguda, Telangana, India. The inspection, which was initially conducted in May 2025, was classified as ‘Voluntary Action Indicated (VAI)’, indicating that the inspection is officially closed. This outcome suggests that while there were some issues noted, they are not significant enough to warrant further regulatory action, which is a positive development for the company’s compliance status and operational stability.
On August 5, 2025, the National Company Law Tribunal in Hyderabad approved the voluntary liquidation of Dr. Reddy’s Laboratories’ wholly-owned subsidiary, Imperial Owners and Land Possessions Private Limited. The dissolution of Imperial, which is not a material subsidiary, will not significantly impact Dr. Reddy’s consolidated financials.
On July 24, 2025, Dr. Reddy’s Laboratories held its 41st Annual General Meeting (AGM) via video conferencing, where key business and financial matters were discussed. The meeting included the adoption of the company’s audited financial statements for the year ending March 31, 2025, and the declaration of a dividend of Rs. 8 per equity share. Additionally, the re-appointment of Mr. G V Prasad as a director and Co-Chairman and Managing Director was approved. The AGM also covered special business items such as the approval of remuneration for cost auditors and the appointment of a new secretarial auditor. The meeting facilitated electronic voting for members to ensure a transparent decision-making process.
On July 24, 2025, Dr. Reddy’s Laboratories announced the publication of its unaudited financial results for the quarter ending June 30, 2025. The results were advertised in the Financial Express and Andhra Prabha newspapers, highlighting the company’s ongoing transparency and compliance with regulatory requirements. This announcement underscores Dr. Reddy’s commitment to maintaining investor confidence and adhering to financial disclosure norms.
On July 24, 2025, Dr. Reddy’s Laboratories announced the re-appointment of Mr. G V Prasad as Co-Chairman and Managing Director for a five-year term starting January 30, 2026. This decision, approved by the shareholders at the company’s 41st AGM, underscores the company’s commitment to leadership continuity and strategic growth, leveraging Mr. Prasad’s extensive experience in the pharmaceutical industry.
On July 24, 2025, Dr. Reddy’s Laboratories announced that its shareholders approved the appointment of Makarand M. Joshi & Co. as the Secretarial Auditors for a five-year term starting April 1, 2025. This decision, made during the company’s 41st Annual General Meeting, underscores Dr. Reddy’s commitment to maintaining robust corporate governance practices, potentially enhancing its credibility and operational transparency in the pharmaceutical industry.
On July 23, 2025, Dr. Reddy’s Laboratories announced the availability of audio recordings from their earnings call for the quarter ending June 30, 2025. The announcement is part of their regulatory compliance under the Securities and Exchange Board of India regulations, indicating transparency and communication with stakeholders. This move is likely to impact stakeholders by providing insights into the company’s financial performance and strategic direction.
On July 23, 2025, Dr. Reddy’s Laboratories announced its intention to appoint Deloitte Haskins & Sells LLP as its Statutory Auditors for five years starting from FY 2026-27. This decision, pending regulatory approval, marks a strategic move as the company transitions from its current auditors, M/s. S.R. Batliboi & Associates LLP, whose term concludes at the 42nd AGM in 2026. The appointment reflects Dr. Reddy’s commitment to maintaining high standards of audit independence and compliance, potentially impacting its operational transparency and stakeholder confidence.
On July 23, 2025, Dr. Reddy’s Laboratories announced the presentation of its unaudited financial results for the first quarter of the fiscal year 2026, which ended on June 30, 2025. This announcement is part of the company’s compliance with the Securities and Exchange Board of India’s regulations and aims to keep stakeholders informed about its financial performance. The release of these results could impact the company’s market positioning and provide insights into its operational strategies.
Dr. Reddy’s Laboratories released its quarterly report for the period ending June 30, 2025, detailing its financial performance and operations. The report, reviewed by Ernst & Young Associates LLP, indicates no material modifications required for compliance with International Accounting Standards. This quarterly review highlights the company’s stable financial position and adherence to regulatory standards, which could positively impact its market reputation and stakeholder confidence.
On July 23, 2025, Dr. Reddy’s Laboratories announced its financial results for the quarter ending June 30, 2025. The company released unaudited consolidated and standalone financial results in accordance with both International Financial Reporting Standards (IFRS) and Indian Accounting Standards (Ind AS). This disclosure, following a board meeting, highlights the company’s commitment to transparency and regulatory compliance, potentially impacting its market positioning and stakeholder confidence.
On July 22, 2025, Dr. Reddy’s Laboratories announced the publication of a newspaper advertisement regarding the opening of a special window for the re-lodgment of transfer requests for physical shares. This initiative, published in Business Standard and Nava Telangana, is in compliance with SEBI’s regulations and aims to facilitate the transfer process for stakeholders, reflecting the company’s commitment to regulatory adherence and shareholder engagement.
On July 21, 2025, Dr. Reddy’s Laboratories announced that the United States Food & Drug Administration (USFDA) has completed its inspection of the company’s API facility in Middleburgh, New York. The inspection, which took place earlier in the year, resulted in a classification of ‘Voluntary Action Indicated (VAI)’ and is now officially closed. This outcome indicates that while some issues were noted, they do not require immediate corrective action and the facility continues to operate within acceptable standards. This development is significant for Dr. Reddy’s as it reinforces the company’s compliance with US regulatory standards, potentially strengthening its market position in the United States.